How are you incorporating the newer RCT data suggesting no mortality benefit to indefinite beta-blocker therapy for patients who are several years out from an MI with preserved LVEF and no angina or arrhythmia?

As per the REDUCE-AMI trial.

Are you routinely de-prescribing, selectively stopping based on symptoms or risk profile, or still continuing by default?